Schizophrenia Research

A selective approach to theories of pathogenesis and aetiology of schizophrenia
pp. 93-93(1)
Author: Crow T.J.

The common evolutionary origins of language and psychosis: the gene under selective pressure
pp. 93-93(1)
Authors: Crow T.J.; Crow L.R.; Done D.J.

The maturational theory of brain development and manic depressive psychosis and schizophrenia
pp. 93-94(2)
Author: Saugstad L.F.

Chemical signaling disorders in the brain
pp. 94-94(1)
Author: Saugstad L.F.

The inadequacy of the simple neurodevelopmental model
pp. 94-94(1)
Author: Murray R.M.

An animal model for neurodevelopmental disorders; behavioural evaluation
pp. 94-95(2)
Authors: Talamini L.M.; Ellenbroek B.

An animal model for neurodevelopmental disorders: morphological evaluation.
pp. 95-95(1)
Authors: Talamini L.M.; Buiskool M.

Autoimmune diseases and schizophrenia co-segregate within schizophrenic pedigrees
pp. 95-95(1)
Authors: Wright P.; Gilvarry C.M.; Jones P.B.; Cannon M.; Sham P.C.; Murray R.M.

Risk of schizophrenia in male subjects with a history of obstetric complications and their siblings: a controlled study
pp. 97-97(1)
Authors: Bersani G.; Taddei I.; Venturi P.; Pancheri P.; Cattaruzza M.S.

Obstetric complications in schizophrenia and mania: a comparative study
pp. 97-97(1)
Authors: Byrne M.; Morris M.; Browne R.; Mulryan N.; Scully A.; McDonald E.; Duffin Y.; Kinsella A.; Walsh D.; McNeil T.F.; Larkin C.; O'Callaghan E.

Maternal demographic correlates of increased history of obstetric complications in schizophrenia
pp. 97-97(1)
Authors: Cantor-Graae E.; McNeil T.F.; Sjostrom K.; Nordstrom L.; Rosenlund T.

Obstetric complications and schizophrenia: a meta-analysis
pp. 98-98(1)
Authors: Geddes J.R.; Lawrie S.M.

Schizophrenia and other psychiatric disorders following pregnancy and delivery complications: a follow-up of the 1966 North Finland birth cohort
pp. 98-98(1)
Authors: Jones P.B.; Rantakallio P.; Hartikainen A.-L.; Isohanni M.; Sipila P.

Increased obstetric complications in schizophrenia in a Japanese sample
pp. 98-99(2)
Authors: Kunugi H.; Takei N.; Murray R.M.; Nanko S.; Saito K.; Akizuki S.

Chicken or egg in schizophrenia's etiology: does pre-existing abnormality cause labor-delivery complications in fetuses who will become schizophrenic and in fetuses at genetic risk?
pp. 99-99(1)
Authors: McNeil T.F.; Cantor-Graae E.

Does choice of scale for scoring obstetric complications influence their relationship to other etiological risk factors in schizophrenia?
pp. 99-99(1)
Authors: McNeil T.F.; Cantor-Graae E.; Nordstom L.G.; Rosenlund T.

Are reduced head circumference at birth and increased obstetric complications associated only with schizophrenic psychosis?: a comparison with schizo-affective and unspecified functional psychosis
pp. 99-99(1)
Authors: McNeil T.F.; Cantor-Graae E.; Nordstrom L.G.; Rosenlund T.

Obstetric complications and brain changes in schizophrenia
pp. 100-100(1)
Authors: Smith G.N.; MacEwan G.W.; Altman S.; Lapointe J.S.; Kopala L.; Flynn S.W.; Honer W.G.

Obstetric complications, premorbid and current cognitive functioning in schizophrenics and their same-sex healthy siblings
pp. 100-100(1)
Authors: Willinger U.; Heiden A.; Meszaros K.; Stompe T.; Miller-Reiter E.; Lenzinger E.; Resinger E.; Aschauer H.N.

Maternal influenza, obstetric complications, birth weight and schizophrenia
pp. 100-100(1)
Authors: Wright P.; Takei N.; Rifkin L.; Murray R.M.

The seasonality of schizophrenic births in Barbados
pp. 100-101(2)
Authors: Malesu R.R.; Mckenzie K.; Murray R.

Seasonality of schizophrenic births and stillbirths in the Netherlands
pp. 101-101(1)
Authors: Selten J.P.; van der Graaf Y.

Family history of psychosis and season of birth in catatonic schizophrenia
pp. 101-101(1)
Authors: Mimica N.; Folnegovic-Smalc V.; Folnegovic Z.

Season of birth and the age incidence effect: is it real or imagined
pp. 101-102(2)
Authors: Welham J.; McGrath J.; Pemberton M.

Winter birth excess in schizophrenics born in French urban areas
pp. 102-102(1)
Authors: Verdoux H.; Takei N.; de Saint Mathurin R.C.; Murray R.; Bourgeois M.

The increased risk of psychosis in African-Caribbean migrants to the UK: a replication
pp. 102-102(1)
Authors: Harrison G.; Brewin J.; Cantwell R.; Dalkin T.; Fox R.; Medley I.; Walder C.

There is a higher morbid risk of schizophrenia in the siblings of 2nd generation Caribbean schizophrenic probands compared to white counterparts
pp. 102-103(2)
Authors: Hutchinson G.; Takei N.; Fahy T.; Bhugra D.; Moran P.; Murray R.M.

The high rates of psychosis among the Caribbean population in the UK are not attributable to any excess of obstetric complications
pp. 103-103(1)
Authors: Hutchinson G.; Takei N.; Fahy T.; Bhugra D.; Moran P.; Murray R.M.

Increased rates of schizophrenia and other mental disorders among emigrants: some methodological considerations
pp. 103-103(1)
Authors: Mortensen P.B.; Cantor-Graae E.; McNeil T.F.

Point prevalence of schizophrenia in immigrant groups in Rotterdam
pp. 103-104(2)
Authors: Schrier A.C.; Selten J.P.; van de Wetering B.J.M.; Mulder P.G.H.

Sex differences in the incidence of schizophrenia in Surinamese immigrants to the Netherlands
pp. 104-104(1)
Authors: Selten J.P.; Slaets J.P.J.

The relationship between temperature and schizophrenia birthrates
pp. 105-105(1)
Authors: Auliciems A.; Welham J.; McGrath J.; MacLachlan G.

The 'seasonality' of month-of-first-admission for schizophrenia
pp. 105-105(1)
Authors: McGrath J.; Welham J.; Ahmed F.

Heatwaves during pregnancy as a risk factor for schizophrenia
pp. 105-105(1)
Authors: Bark N.M.; Krivelevich I.

Schizophrenia in Nottingham 1978-1994: secular trends in incidence
pp. 106-106(1)
Authors: Brewin J.S.; Harrison G.L.; Cantwell R.; Dalkin T.; Fox R.; Glazebrook C.; Medley I.

Cyclical trends in admissions of the functional psychoses
pp. 106-106(1)
Authors: Moran P.; Takei N.; Morris M.; O'Callaghan E.

Explaining sex differences in course and outcome in the functional psychoses
pp. 106-106(1)
Authors: Navarro F.; van Os J.; Jones P.; Murray R.

The hampstead schizophrenia survey 1991: incidence and migration in Inner London
pp. 107-107(1)
Authors: McNaught A.S.; Jeffreys S.; Harvey C.A.; Quayle A.S.; King M.B.

Urban residence as a risk factor for psychosis in the 1880 United States census
pp. 107-107(1)
Authors: Torrey E.F.; Waldman I.N.; Clark K.

Geographic variation in rate of schizophrenia by place of birth vs place at onset of illness in rural Ireland, and its gender characteristics
pp. 107-107(1)
Authors: Youssef H.A.; Kinsella A.; Waddington J.L.; Scully P.

Schizophrenia in Nottingham: alcohol and drug misuse comorbidity
pp. 108-108(1)
Authors: Cantwell R.; Brewin J.; Dalkin T.; Fox R.; Glazebrook C.; Kwiecinski R.; Harrison G.L.

Substance abuse: cause or consequence of schizophrenia?
pp. 108-108(1)
Authors: Hambrecht M.; Hafner H.

Dual diagnosis in admissions to Psychiatric Hospital, Barbados
pp. 108-108(1)
Author: Malesu R.R.

Substance misuse among schizophrenics in the community: a follow-up study using hair analysis
pp. 109-109(1)
Authors: McPhillips M.A.; Kelly F.; Barnes T.R.E.; Gene-Cos N.; Duke P.; Clarke K.

Self-reported substance and attitude to drug treatment
pp. 109-109(1)
Authors: Stedman T.; Welham J.; Mercer D.; Vacca J.; Haire M.

Suicide within 12 months of discharge in schizophrenic patients, Scotland 1968-1992
pp. 109-109(1)
Authors: Geddes J.R.; Juszczak E.

Mortality in current and former users of clozapine
pp. 110-110(1)
Authors: Lanza L.L.; Walker A.M.; Arellano F.; Rothman K.J.

Association between extent of neuroleptic polypharmacy and reduced survival in a 10-year prospective study of mortality in schizophrenia
pp. 110-110(1)
Authors: Youssef H.A.; Kinsella A.; Waddington J.L.

Gender differences in long-term outcome of schizophrenia
pp. 110-110(1)
Authors: Croudace T.J.; Mason P.; Harrison G.

Further tests on the estrogen hypothesis
pp. 111-111(1)
Author: Hafner H.

Is the earlier age at onset of schizophrenia in males a confounded finding?
pp. 111-111(1)
Authors: Jablensky A.; Cole S.W.

Explaining sex differences in course and outcome in the functional psychoses
pp. 111-112(2)
Authors: Navarro F.; van Os J.; Jones P.; Murray R.

Reproductive history in women with schizophrenia across cultures
pp. 112-112(1)
Authors: Yellachich L.; Jablensky A.

Epilepsy and schizophrenia
pp. 112-112(1)
Authors: Bredkjaer S.R.; Mortensen P.B.; Parnas J.

Hospitalization and medication usage in elderly schizophrenic and bipolar patients over a ten year period
pp. 112-112(1)
Authors: Sajatovic M.; Popli A.; Semple W.

Evidence for similar developmental precursors of chronic affective illness and schizophrenia in a general population birth cohort
pp. 113-113(1)
Authors: van Os J.; Jones P.; Lewis G.; Wadsworth M.; Murray R.

Does familiarity predispose to both emergence and persistence of psychosis? A prospective study
pp. 113-113(1)
Authors: Verdoux H.; van Os J.; Sham P.C.; Jones P.B.; Gilvarry K.; Murray R.

Symptom structure in schizophrenia: two or three-factor models?
pp. 115-115(1)
Authors: Dollfus S.; Everitt B.; Petit M.

Factor derived sub-syndromes of schizophrenia and familial morbid risks
pp. 115-115(1)
Authors: Cardno A.G.; Holmans P.A.; Harvey I.; Williams M.B.; Owen M.J.; McGuffin P.

Four behavioural syndromes of schizophrenia
pp. 115-116(2)
Authors: Harvey C.A.; Curson D.A.; Pantelis C.; Taylor J.; Barnes T.R.E.

The long-term stability of the deficit syndrome
pp. 116-116(1)
Authors: Amador X.F.; Kirkpatrick B.; Carpenter W.T.; Yale S.A.; Marcinko L.

Subjective and objective ratings for negative symptoms
pp. 116-116(1)
Authors: Selten J.P.; Gernaat H.B.P.E.; van den Bosch R.J.

Subsyndromes of schizophrenia in old age
pp. 116-117(2)
Authors: Sauer H.; Hornstein C.; Richter P.; Mortimer A.; Beuth A.; Muller-Wulff J.; Will A.

Choosing a negative symptom rating scale
pp. 117-117(1)
Authors: Welham J.; Smith G.; Stedman T.; Clair A.

Course, correlates and predictors of depression in schizophrenia
pp. 117-117(1)
Authors: Addington D.; Addington J.; Patten S.

Suicidal behavior and insight in schizophrenia
pp. 117-117(1)
Authors: Amador X.F.; Friedman J.H.; Flaum M.; Gorman J.M.

Neuropsychological and defensive aspects of poor insight and depression in schizophrenia
pp. 117-118(2)
Authors: Kasapis C.; Amador X.F.; Yale S.A.; Strauss D.H.; Gorman J.M.

'Catatonic schizophrenia' is not 'schizophrenia'
pp. 118-118(1)
Author: Fink M.

Schizophrenia and its catatonic subtype instability during long-term follow-up
pp. 118-118(1)
Author: Mimica N.

The Peters et al. delusions inventory (PDI): new norms for the 21-item version
pp. 118-119(2)
Authors: Peters E.R.; Garety P.A.

Dimensions of schizotypy
pp. 119-119(1)
Author: Hopkins R.S.

Increased schizotypy scores in normal subjects following the oral administration of d-amphetamine
pp. 119-119(1)
Authors: Gray N.S.; Pickering A.D.; Gray J.A.

Syndromes of schizotypy and age at sexual maturity
pp. 119-120(2)
Authors: Gruzelier J.H.; Kaiser J.

Non-verbal behaviour patterns of schizophrenic patients: analysis, empirical findings, and perspectives for therapeutic interventions
pp. 120-120(1)
Authors: Altorfer A.; Jossen S.

Illness awareness in outpatients with schizophrenia
pp. 120-120(1)
Authors: Dickerson F.B.; Boronow J.J.; Ringel N.; Parente F.

Diagnostic concordance for schizophrenia according to DSM and ICD criteria
pp. 120-121(2)
Author: Flaum M.

The relationship between schizophrenia and frontal lobe deficits in a forensic population: a case study
pp. 121-121(1)
Authors: Gilluley P.F.; Gray N.S.; James D.V.

Subtyping of schizoaffective disorder
pp. 121-121(1)
Authors: Kegeles L.S.; Gorman J.M.; Yale S.A.; Bracha H.S.; Flaum M.; McGorry P.D.; Amador X.F.

Testing the validity of possible pre-morbid clinical indicators of schizophrenia vulnerability
pp. 121-122(2)
Author: Meurice E.

Cross cultural perceptions of schizophrenia
pp. 122-122(1)
Authors: Pote H.L.; Orrell M.

Endogeneous and exogeneous 'schizophrenias'
pp. 122-122(1)
Author: Saugstad L.F.

Paraphrenia revisited
pp. 122-123(2)
Authors: Stevens J.R.; Bruton C.J.; Royston M.C.

Diagnostic shift between schizophrenia and affective disorders in a Universitary Mental Hospital in Sao Paulo, Southeast Brazil
pp. 123-123(1)
Authors: de Toledo M.L.; Elkis H.

Main characteristics of subjects who have recovered from schizophrenia
pp. 123-123(1)
Author: Torgalsboen A.K.

Anxiety and schizophrenia
pp. 123-124(2)
Authors: Weller M.P.I.; Wright S.

Clozaril (Clozapine) associated neutropenia and agranulocytosis
pp. 125-125(1)
Authors: Atkin K.J.; Kendall F.; Arellano F.; O'Sullivan D.P.; Krupp P.

'High dose' clozapine therapy: clinical and biochemical correlates
pp. 125-125(1)
Authors: Buckley P.F.; Krowinski A.C.; Miller D.; Friedman L.; Eaton E.; Tronetti M.

Eosinophilia on commencement of clozapine treatment
pp. 125-125(1)
Author: Chatterton R.P.

Termination of clozapine treatment
pp. 125-126(2)
Authors: Kurz M.; Hummer M.; Oberbauer H.; Kurzthaler I.; Fleischhacker W.W.

The effect of clozapine on the course of illness in chronic schizophrenia: focus on treatment outcome in open-care patients
pp. 126-126(1)
Authors: Joffe G.; Venalainen E.; Tupala J.; Hiltunen O.; Wahlbeck K.; Gadeke R.; Rimon R.

Clozapine versus treatment as usual in schizophrenia
pp. 126-126(1)
Authors: Dye S.M.; Lock M.; Mortimer A.M.

Hepatotoxicity of clozapine
pp. 126-127(2)
Authors: Hummer M.; Oberbauer H.; Kurz M.; Kurzthaler I.; Schnegg G.; Fleischhacker W.W.

A double-blind, randomized trial comparing clozapine treatment within three distinct serum level ranges in patients with refractory chronic schizophrenia
pp. 127-127(1)
Authors: McEvoy J.P.; VanderZwaag C.; McGee M.; Freudenreich O.; Wilson W.H.; Cooper T.B.

Efficacy of clozapine versus haloperidol in a long-term clinical trial
pp. 127-127(1)
Authors: Kane J.M.; Schooler N.R.; Marder S.; Wirshing W.; Ames D.; Umbricht D.; Safferman A.; Baker R.; Ganguli R.

Combined clozapine-lithium treatment in schizophrenia and schizoaffective disorder
pp. 127-127(1)
Authors: Moldavsky M.; Stein D.; Benatove R.; Sirota P.; Weizman A.; Elizur A.

Two year follow-up of effectiveness of clozapine on long-term neuroleptic-resistant hospitalized patients: naturalistic study
pp. 128-128(1)
Authors: Rabinowitz J.; Avnon M.

Schizophrenia, clozapine and IILA in Israeli Jewish patients
pp. 128-128(1)
Authors: Meged S.; Stein D.; Sirota P.; Elizur A.; Gazit E.

Effect of clozapine on physical and verbal aggression
pp. 128-128(1)
Authors: Rabinowitz J.; Avnon M.

Heart rate variability in schizophrenic patients: effect of clozapine
pp. 128-129(2)
Authors: Zimmermann U.; Rechlin T.; Kaschka W.P.

Subjective response to risperidone and haloperidol: preliminary results
pp. 129-129(1)
Authors: Ames D.; Wirshing W.C.; Marder S.R.; Hwang S.S.; German C.A.; Strough A.B.

Risperidone vs. haloperidol: relative liabilities for OCD and depression
pp. 129-129(1)
Authors: Ames D.; Wirshing W.C.; Marder S.R.; Hwang S.S.; German C.A.; Mintz J.; Goldstein D.

A retrospective evaluation of risperidone use in a community based psychiatric service
pp. 129-130(2)
Authors: Denihan C.; Browne S.; Kinsella A.; Larkin C.; O'Callaghan E.

Efficacy of risperidone at lower doses: a pilot study
pp. 130-130(1)
Authors: Labelle A.; Boulay L.J.; Jones B.D.; Patel S.

Risperidone vs. haloperidol in treatment resistant schizophrenia: preliminary results
pp. 130-130(1)
Authors: Wirshing W.C.; Ames D.; Marder S.R.; Marshall B.D.; Green M.F.; McGurk S.

Quality of life outcomes of olanzapine, a new atypical antipsychotic agent
pp. 130-131(2)
Authors: Martin C.; Genduso L.; Revicki D.; Hamilton S.; Tran P.; Beasley C.

The effect of olanzapine on cognition and psychomotor function in healthy elderly volunteers
pp. 131-131(1)
Authors: Taylor N.; Beuzen J.N.; Wesnes K.; Wood A.

Olanzapine versus haloperidol: results of the multi-center international trial
pp. 131-131(1)
Authors: Tollefson G.D.; Beasley C.M.; Tran P.V.; Tamura R.N.; Sanger T.M.; Wood A.; Beuzen J.N.

A comparison of five fixed doses of 'seroquel' (ICI 204,636) with haloperidol and placebo in patients with schizophrenia
pp. 132-132(1)
Authors: Borison R.L.; Arvanitis L.A.; Miller B.G.

ICI 204636 ('Seroquel')--a putative new atypical antipsychotic: results from phase III trials
pp. 132-132(1)
Authors: Hurst B.C.; Fleischhacker W.W.; Linkz C.G.G.

Ziprasidone--safety and efficacy
pp. 132-133(2)
Author: Gunn K.P.

Efficacy, safety and tolerance of a D₁ antagonist SCH 39 66 in 6 cases of acute psychotic states
pp. 133-133(1)
Authors: Labelle A.; de Beaurepaire R.; Boulay L.J.; Jones B.D.; Naber D.; Barnes T.R.E.

A comparison of an atypical (zotepine) and classical (haloperidol) antipsychotic, in patients with acute exacerbation of schizophrenia
pp. 133-133(1)
Authors: Raniwalla J.; Tweed J.A.; Dollfus S.; Petit M.

Efficacy, safety, and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients
pp. 133-134(2)
Authors: Schulz S.C.; Mack R.; Zborowski J.; Morris D.; Sebree T.; Wallin B.

Dose response of oral D-cycloserine in unmedicated and medicated schizophrenics
pp. 134-134(1)
Authors: D'Souza D.C.; White J.; Abi-Saab D.; Damon D.; Gil R.; Zuzarte E.; Krystal J.

Tolerance and efficacy of D-cycloserine in drug-free schizophrenic patients
pp. 134-134(1)
Authors: Van Berckel B.N.M.; Hijman R.; van der Linden J.A.; Westenberg H.G.M.; van Ree J.M.; Kahn R.S.

Different relapse criteria in schizophrenic disorders
pp. 134-135(2)
Authors: Linszen D.H.; Dingemans P.M.; Nugter M.A.; Lenior M.E.; Scholte W.F.; Van der Does A.J.W.

Predicting duration of clinical stability following haloperidol withdrawal in schizophrenia
pp. 135-135(1)
Authors: van Kammen D.P.; Kelley M.E.; Gurklis J.A.; Gilbertson M.W.; Yao J.K.; Condray R.; Peters J.L.

The cochrane schizophrenia group
pp. 135-135(1)
Authors: Adams C.E.; Anderson J.; Mari J.; Seifas R.

A randomised controlled trial of compliance therapy in psychosis: follow-up results and predictors of outcome
pp. 135-135(1)
Authors: Kemp R.; Kirov G.; Hayward P.; David A.

Treatment response to haloperidol and family history
pp. 136-136(1)
Authors: Labelle A.; Alda M.; Boulay L.; Lafontaine S.; Patel S.

The effect of SSRI augmentation of antipsychotics in the treatment of negative symptoms
pp. 136-136(1)
Author: Silver H.

Application of propranolol in the management of aggression in schizophrenic patients
pp. 136-136(1)
Authors: Stein D.; Meged S.; Sirota P.; Levine J.; Elizur A.; Maoz G.; Berger B.

Issues in finding and keeping randomised controlled trials (RCTs)
pp. 137-137(1)
Author: White P.V.

Role of endotoxicosis in pathohenetic mechanisms of schizophrenia and in formation of therapy-resistance to psychotropic drugs
pp. 137-137(1)
Authors: Malin D.I.; Uzbekov N.G.; Misionzhnic E.Y.; Mosolov S.N.

Low doses of amisulpride in lobules 9 and 10 of the cerebellum stimulate locomotor activity: a role for dopamine D3 receptors
pp. 139-139(1)
Authors: de Beaurepaire R.; Barik S.

The atypical antipsychotic olanzapine is an antagonist at dopamine, serotonin and muscarinic receptor subtypes
pp. 139-139(1)
Authors: Bymaster F.P.; Nelson D.L.; DeLapp N.W.; Lucaites V.L.; Wainscott D.B.; Falcone J.F.; Eckols K.; Foreman M.M.; Calligaro D.O.

Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg 'Seroquel' TID
pp. 139-140(2)
Authors: Gefvert O.; Lindstrom L.H.; Langstrom B.; Bergstrom M.; Lundberg T.; Yates R.A.

The receptor binding profile of MDL 100,907
pp. 140-140(1)
Authors: Baron B.M.; Johnson M.P.; van Giersbergen P.L.M.; Elands J.; Sorensen S.M.

New dopamine- and serotonin receptor subtypes, targets for antipsychotics drugs in vivo?
pp. 140-140(1)
Authors: Leysen J.E.; Gommeren W.; Janssen P.M.F.; Schotte A.

The pharmacologic properties of 'Seroquel' (ICI 204,636) are clozapine-like in new tests for atypical antipsychotic actions
pp. 140-140(1)
Author: Goldstein J.M.

Comparison of the 5-HT_2A antagonist MDL 100,907 with typical and atypical antipsychotics in phencyclidine- and amphetamine-stimulated locomotion tests in mice
pp. 141-141(1)
Authors: Hitchcock J.M.; Grauffel C.A.

Dopamine₂- and serotonine₂-receptor-antagonism by antipsychotics in man
pp. 141-141(1)
Authors: Coppens H.J.; Louwerens J.W.; Slooff C.J.; Korf J.; Paans A.M.J.

Binding of zotepine to serotonin (5-HT) receptor subtypes
pp. 141-141(1)
Authors: Needham P.L.; Atkinson J.; Cheetham S.C.; Dinnis D.; Slater N.A.; O'Brien E.; Heal D.J.

Binding of atypical antipsychotic drugs to novel neurotransmitter receptors
pp. 142-142(1)
Authors: Roth B.L.; Hamblin M.W.; Sibley D.R.; Meltzer H.Y.

Rationale for the use of a selective 5-HT_2A receptor antagonist in the treatment of schizophrenia
pp. 142-142(1)
Authors: Schmidt C.J.; Fadayel G.M.; Sorensen S.M.; Kehne J.H.

Therapeutic receptor-blocking concentrations of neuroleptics
pp. 142-143(2)
Authors: Seeman P.; van Tol H.H.M.

Preclinical profile of MDL 100 907, a potent and selective 5-HT_2A antagonist in development for schizophrenia
pp. 143-143(1)
Authors: Sorensen S.M.; Carr A.A.; van Giersbergen P.L.M.; Hitchcock J.M.; Kehne J.H.; Schmidt C.J.

Combined 5-HT₂/D₂ receptor antagonism in brain: physiological, biochemical and behavioural significance
pp. 143-143(1)
Authors: Svensson T.H.; Ahlenius S.; Hertel P.; Mathe J.M.; Marcus M.; Nomikos G.G.; Salmi P.; Wadenberg M.-L.

Metabolites of clozapine inhibit the replication of neurotropic viruses
pp. 143-144(2)
Authors: Brando L.V.J.; Holland L.E.; Carbone K.M.; Yolken R.H.; Torrey E.F.

Low serum cholesterol and treatment-resistance in schizophrenia
pp. 144-144(1)
Authors: Dursun S.M.; Boston P.F.; Zafar R.; Reveley M.A.

Clozapine, but not typical antipsychotic drugs, reduces impulsivity and increases platelet serotonin levels in schizophrenia
pp. 144-145(2)
Authors: Dursun S.M.; Szemis A.; Andrews H.; Reveley M.A.

Effect of typical and atypical neuroleptics on fos protein expression in the rat forebrain
pp. 145-145(1)
Authors: Fink-Jensen A.; Ludvigsen T.S.; Korsgaard N.; Kristensen P.

Preclinical tests that predict clozapine-like atypical antipsychotic actions
pp. 145-145(1)
Author: Goldstein J.M.

Direct evidence that reduced accumbens dopamine function potentiates latent inhibition: a model of antipsychotic action with construct validity
pp. 145-146(2)
Authors: Joseph M.H.; Peters S.L.; Grigoryan G.A.; Boulenguez P.; Gray J.A.

Gender differences in psychotic symptom response to neuroleptic drugs
pp. 146-146(1)
Authors: Kulkarni J.; Smith D.; de Castella A.

Weight gain and antipsychotics in schizophrenia
pp. 146-146(1)
Authors: Lake M.B.; Ganguli R.; Kuhn B.; Gubbi A.

Effects of chronic treatment with typical and atypical antipsychotic drugs on the caudate nucleus in the rat
pp. 146-147(2)
Authors: H. L.; Tarazi F.I.; Chakos M.; Redmond M.; Kinon B.; Bilder R.; Lieberman J.

Norzotepine: atypical antipsychotic profile of zotepine's major active metabolite
pp. 147-147(1)
Authors: Needham P.L.; Lancashire B.; Skill M.J.; Heal D.J.

Differential cholinergic regulation of dopamine release in dorsal and ventral neostriatum of the rat. Relevance for the antipsychotic efficacy and neuroleptic properties of antipsychotic drugs
pp. 147-147(1)
Author: O'Connor W.T.

Evidence for a selective CCK_A and CCK_B receptor mediated regulation of GABA and dopamine release in rat nucleus accumbens. A combined receptor binding and microdialysis study
pp. 147-148(2)
Authors: Tanganelli S.; Ferraro L.; O'Connor W.T.; Beani L.; Fuxe K.

Higher cerebrospinal fluid angiotensin-converting enzyme levels in neuroleptic-treated than in drug-free schizophrenics
pp. 148-148(1)
Authors: Wahlbeck K.; Ahokas A.; Nikkila H.; Rimon R.

Probable neuroleptic induced tardive dyskinesia in association with combined SSRI and risperidone treatment
pp. 149-149(1)
Authors: Daniel D.G.; Egan M.; Hyde T.

TD and phenylalanine metabolism: sex and age issues
pp. 149-149(1)
Authors: Richardson M.A.; Flynn C.; Reilly M.; Read L.; Suckow R.; Maher T.; Lin S.; Sziraki I.

Schizophrenic symptoms, tardive dyskinesia and its association with cognitive functioning
pp. 149-149(1)
Authors: Shriqui C.L.; Annable L.; Doucet C.

Neuroleptic induced tardive dyskinesia: efficacy of Vitamin E
pp. 150-150(1)
Authors: Soares K.V.S.; McGrath J.J.

Tardive dyskinesia: effect of medication or illness deterioration?
pp. 150-150(1)
Authors: van Os J.; Fahy T.; Jones P.; Harvey I.; Toone B.; Murray R.

HLA as a risk factor for neuroleptic induced tardive dyskinesia in schizophrenia
pp. 150-150(1)
Authors: Wright P.; Donaldson P.T.; Underhill J.A.; Murray R.M.

An investigation into extrapyramidal side effects induced by neuroleptics and their relationship to creatine phosphokinase
pp. 151-151(1)
Authors: Atkins M.; Camprubi M.; Evans J.; Ball S.G.; Riccio M.

Time to onset of extrapyramidal symptoms in first episode of psychosis
pp. 151-151(1)
Authors: H. L.; Chakos M.; Alvir J.M.J.; Lieberman J.A.

Inhibition of complex I activity by neuroleptics parallels extrapyramidal toxicity
pp. 151-151(1)
Authors: Maurer I.C.; Zierz S.; Moller H.-J.

L-Deprenyl treatment of neuroleptic-induced parkinsonism
pp. 152-152(1)
Authors: Rapoport A.; Schwartz M.; Shtein D.; Levin I.; Stir S.; Elizur A.; Sarova I.; Rabey J.M.

HLA as a risk factor for neuroleptic induced parkinsonism in schizophrenia
pp. 152-152(1)
Authors: Wright P.; Donaldson P.T.; Underhill J.A.; Murray R.M.

Neuroleptic sensitivity and enzyme deficiency in two schizophrenic brothers: a case report
pp. 152-152(1)
Authors: Aitchison K.J.; Patel M.; Taylor M.; Murray R.M.; Arranz M.J.; Collier D.A.; Kerwin R.W.

Arachidonic acid (AA) deficiency is independently associated with abnormal involuntary movements (AIMS) in the general population.--A study of men born in 1933
pp. 153-153(1)
Authors: Nilsson A.; Horrobin D.F.; Rosengren A.; Waller L.; Adlerberth A.; Wilhelmsen L.

Functional MRT of akinetic catatonic patients and normal controls during motor activation
pp. 153-153(1)
Authors: Northoff G.; Khoram-Sefat D.; Eckert J.; Travers H.; Hacker H.; Pflug B.

Mirror movements in schizophrenia
pp. 153-153(1)
Authors: Seabourne A.; Hopkins R.S.; Lewis S.W.

The anterior cingulate cortex in schizophrenia: decreased dopamine and possible mechanism for its occurrence
pp. 155-155(1)
Authors: Wyatt R.J.; Masserano J.; Kulaga H.; Karoum F.; Hitri A.; Elkashef A.

A decreased serotonergic responsivity in platelets of drug-free schizophrenic patients
pp. 155-155(1)
Authors: Yao J.K.; van Kammen D.P.; Moss H.B.; Sokulski D.E.

Clinical evidence that GABA is involved with schizophrenia
pp. 155-156(2)
Authors: van Kammen D.P.; Petty F.; Kramer G.L.; Kelley M.E.; Yao J.K.; Gurklis J.A.; Peters J.L.

Cell membrane phospholipid abnormalities in schizophrenia
pp. 156-156(1)
Authors: Doris A.; Coffey I.; Blackwood D.H.R.

Phospholipase A₂ and hypofrontality in schizophrenia
pp. 156-156(1)
Authors: Gattaz W.F.; Brunner J.

A possible relationship between dyslexia and schizophrenia, two disorders in which membrane phospholipid (PL) metabolism is disturbed
pp. 156-156(1)
Author: Horrobin D.F.

Phospholipase-A₂ activity in psychotic patients
pp. 157-157(1)
Authors: Katila H.; Appelberg B.; Rimon R.

Reduced tyrosine transport in schizophrenia
pp. 157-157(1)
Authors: Bjerkenstedt L.; Wiesel F.-A.; Hagenfeldt L.

Tyrosine transport in schizophrenia
pp. 157-158(2)
Authors: Andersson J.; Blomqvist G.; Bjerkenstedt L.; Hagenfeldt L.; Wiesel F.-A.; Wieselgren I.-M.

On the hypoestrogen hypothesis in female schizophrenia: preliminary results
pp. 158-158(1)
Authors: Bergemann N.; Mundt C.; Resch F.; Parzer P.; Nagl I.; Eller A.; Runnenbaum B.

Female psychosis and the menstrual cycle
pp. 158-158(1)
Authors: Gostt K.; de Castella A.; Kulkarni J.

Gender and schizophrenia: a neuroendocrine study of gonadotropin response to naloxone challenge
pp. 158-159(2)
Authors: Kulkarni J.; de Castella A.; Smith D.; Taffe J.

CSF oxytocin- and vasopressin-neurophysin in schizophrenia: relationships with state and trait variables
pp. 159-159(1)
Authors: van Kammen D.P.; Legros J.J.; Kelley M.E.; Yao J.K.; Gilbertson M.W.; Condray R.; Gurklis J.A.; Peters J.L.

Growth effects of a neuroprotective factor in schizophrenia and bipolar disorder
pp. 159-159(1)
Authors: Bates P.; Mahadik S.; Mukherjee S.; Mahadik J.; Correnti E.; Scheffer R.

Low nerve growth factor (NGF) plasma levels in schizophrenic patients: a pilot study
pp. 159-160(2)
Authors: Bersani G.; Aloe L.; Iannitelli A.; Maselli P.; Venturi P.; Garavini A.; Angelucci F.; Bracci-Laudiero L.; Pancheri P.

Nitric oxide, free radicals and polyamines may have a role in the membrane pathology of schizophrenia
pp. 160-160(1)
Authors: Das I.; McDonnell M.; de Fonseka N.; Hirsch S.R.; Ramchand C.N.; Gliddon A.

Relapse and changes in cytokine and antibody production in schizophrenia
pp. 160-160(1)
Authors: Ganguli R.; Rabin B.S.; Brar J.S.; Gubbi A.V.

The niacin flush test in schizophrenia: clinical and biochemical correlates
pp. 160-161(2)
Authors: Horrobin D.F.; Brayshaw N.; Vaddadi K.; Rybakowski J.; Cooper S.E.; Glen A.I.M.

Increased platelet calcium mobilization and nitric oxide synthase activity-implications in schizophrenia
pp. 161-161(1)
Authors: Khan N.S.; Das I.; Puri B.K.; Joyce E.M.; Barnes T.R.E.; Hirsch S.R.; de Belleroche J.

Neurophysiological analysis of movement initiation and monitoring
pp. 161-161(1)
Authors: Baldeweg T.; Spence S.; Haenschel C.; Gruzelier J.

Association studies of the DRD3 dopamine receptor gene and the NT-3 (neurotrophin-3) gene in unrelated schizophrenics
pp. 163-163(1)
Authors: Gaitonde E.J.; Morris A.G.; Sivagnanasundaram S.; McKenna P.J.; Hunt D.M.; Mollon J.D.

The development of a semi-quantitative assay for D4 gene expression
pp. 163-163(1)
Authors: Mulcrone J.; Kerwin R.

Allelic association between a ser-9-gly polymorphism in the D3 receptor gene and schizophrenia
pp. 163-163(1)
Authors: Shaikh S.; Collier D.; Sham P.; Aitchison K.; Ball D.; Gill M.; Kerwin R.

Schizophrenic patients and their mothers exhibit a negative association with HLA DR4
pp. 164-164(1)
Authors: Wright P.; Donaldson P.T.; Underhill J.A.; Doherty D.; Murray R.M.

5-HT2A polymorphisms and mental disorders
pp. 164-164(1)
Authors: Arranz M.J.; Kirov G.; Sodhi M.S.; Ball D.M.; Kerwin R.W.; Collier D.A.

Association between psychoses and allelic variation in the 5-HT2C receptor gene
pp. 164-164(1)
Authors: Sodhi M.S.; Kirov G.; Arranz M.J.; Ball D.M.; Aitchison K.J.; Kerwin R.W.; Collier D.A.

Association between clozapine response and allelic variation in the 5-HT2A and 5-HT2C receptor genes
pp. 165-165(1)
Authors: Sodhi M.S.; Arranz M.J.; Ball D.M.; Roberts G.W.; Collier D.A.; Kerwin R.W.; Price J.

Schizophrenia associated with a genetic variant in cytosolic PLA2
pp. 165-165(1)
Authors: Hudson C.J.; Kennedy J.L.; Skoreki K.; Horrobin D.F.

A transmission disequilibrium study on catechol-O-methyltransferase polymorphism in schizophrenia families
pp. 165-165(1)
Authors: Kunugi H.; Vallada H.P.; Curtis D.; Arranz M.; Nanko S.; Murray R.M.; Owen M.; McGuffin P.; Gill M.; Collier D.A.

Association of polymorphic microsatellite region in the first intron of the human tyrosine hydroxylase gene with disturbances of the catecholaminergic system in schizophrenia
pp. 166-166(1)
Authors: Thibaut F.; Ribeyre J.M.; Dourmap N.; Dollfus S.; Campion D.; Petit M.; Laurent C.; Meloni R.

Linkage disequilibrium studies of D22S278 genotypes in 574 pedigrees
pp. 166-166(1)
Authors: Vallada H.; Gill M.; Collier D.

Search for linkage to X and Y chromosomes in families with schizophrenia and schizoaffective disorder
pp. 166-167(2)
Authors: Dann J.C.; DeLisi L.E.; De Voto M.; Loftus J.; Prosho L.; Smith A.; Shields G.; Laval S.; Rue J.; Vita A.; Morganti C.; Ott J.; Crow T.J.

Evaluation of a susceptibility gene for schizophrenia on chromosome 6P
pp. 167-167(1)
Authors: Wildenauer D.; Maier W.; Albus M.; Schwab S.; Hallmayer J.; Ebstein P.; Risch N.; Lerer B.

Preliminary results from a linkage study of the N-methyl-D-aspartate (NMDA) receptor subunit genes in a sample of southern African Bantu-speaking families multiply affected with schizophrenia
pp. 167-167(1)
Authors: Riley B.P.; Tahir E.; Rajagopalan S.; Williamson R.; Mogudi-Carter M.; Faure S.; Weissenbach J.; Jenkins T.

Association of CAG repeat expansions with clinical features of schizophrenia
pp. 168-168(1)
Authors: Morris A.G.; Gaitonde E.; McKenna P.J.; Mollon J.D.; Hunt D.M.

A pet study of glucose metabolism in brain areas implicated in schizophrenia: effects of X chromosome triplet repeats
pp. 168-168(1)
Authors: Murphy D.G.M.; Xenetidis K.; Henry J.; Mentis M.J.; Rapoport S.I.

Retroviral mutagenesis could explain the familial and population patterns of schizophrenia: molecular assay
pp. 168-169(2)
Authors: Deb P.; O'Reilly R.L.; Singh S.M.

Dermatoglyphic a-b ridge count and risk for schizophrenia
pp. 169-169(1)
Authors: Fananas L.; Bertranpetit J.; Van Os J.; Hoyos C.; McGrath J.; Murray R.M.

Dermatoglyphic abnormalities in schizophrenia
pp. 169-169(1)
Authors: Fearon P.; Lane A.; Airey M.; Scannell J.

Quantitative evidence of developmental instability in schizophrenia as measured by fluctuating asymmetry
pp. 169-170(2)
Authors: Lane A.; Kinsella A.; Waddington J.L.; Larkin C.; O'Callaghan E.

Minor physical anomalies in schizophrenic patients and their relatives
pp. 170-170(1)
Authors: Griffiths T.; Birkitt P.; Sharma T.; Frangou S.; Revely A.; Murray R.; Sigmundsson T.

Location of the handedness gene on the X and Y chromosomes
pp. 170-170(1)
Authors: Corballis M.C.; Lee K.; McManus I.C.; Crow T.J.

A new and familial variant of schizophrenia?
pp. 170-171(2)
Authors: Doody G.A.; Muir W.J.; Johnstone E.C.; Owens D.G.C.

Learning difficulties in familial schizophrenia
pp. 171-171(1)
Authors: Glen A.I.M.; Glen E.M.T.; MacDonell L.E.F.; Skinner F.K.; Sutherland J.; Ward P.E.

Syndrome structure in schizophrenia is independent of genetic predisposition
pp. 171-171(1)
Authors: Loftus J.B.; Bass N.J.; DeLisi L.E.; Crow T.J.

A study of monozygotic twins discordant and concordant for psychotic illness examining dermatoglyphic risk factors for psychosis
pp. 172-172(1)
Authors: van Os J.; Fananas L.; Cannon M.; Murray R.

Dopamine D₂, D₃, D₄ receptors in human postmortem brain sections: comparison between normals and schizophrenics
pp. 173-173(1)
Authors: Lahti R.A.; Roberts R.C.; Conley R.R.; Tamminga C.A.

Distribution of dopamine D₄ receptor in human postmortem brain sections: autoradiographic studies with [³H]-NGD-94-1
pp. 173-173(1)
Authors: Lahti R.A.; Primus R.J.; Gallager D.W.; Roberts R.; Tamminga C.A.

Dopamine D4 receptor elevation in schizophrenia -- fact or artifact?
pp. 173-173(1)
Authors: Reynolds G.P.; Mason S.L.; Tillery C.

Increased glutamatergic innervation of entorhinal cortex in schizophrenia
pp. 174-174(1)
Authors: Longson D.; Deakin J.F.W.; Benes F.M.

Non-NMDA glutamate receptor expression in schizophrenia
pp. 174-174(1)
Authors: Eastwood S.L.; Porter R.H.P.; Burnet P.W.J.; Kerwin R.W.; Harrison P.J.

The expression of the N-methyl-D-aspartate receptor subunit NR-1 messenger RNA in schizophrenia
pp. 174-175(2)
Authors: Humphries C.R.; Mortimer A.; Barnes T.; Hirsch S.; de Belleroche J.

Distribution of excitatory and inhibitory markers in the human entorhinal cortex using in-situ hybridisation histochemistry
pp. 175-175(1)
Authors: Longson D.; Longson C.M.; Deakin J.F.W.; Jones E.G.

Decreased glutamatergic binding sites in the left orbito-frontal cortex of chronic schizophrenics
pp. 175-175(1)
Authors: von Bussmann K.A.; Rodway A.; Gentleman S.M.; Garey L.J.; Hirsch S.R.

The distribution of creatine kinase BB in brain of patients with schizophrenia
pp. 175-176(2)
Authors: Burbaeva G.S.; Karaseva N.S.; Savushkina O.K.

Investigation of gliosis in the dorsal raphe nucleus of schizophrenics
pp. 176-176(1)
Authors: C. P.L.-H.C.; Dagg B.; Cooper S.J.; Esiri M.M.

Is the expression of cholecystokinin mRNA in schizophrenia region specific?
pp. 176-176(1)
Authors: Durnin A.T.; Mortimer A.; Barnes T.R.E.; Hirsch S.R.; deBelleroche J.

Somatostatin in TD and schizophrenia. A morphometric post-mortem-study
pp. 176-177(2)
Authors: Falkai P.; Tapernon-Franz U.; Pilz K.; Schneider T.; Bogerts B.

Brain libraries indicate differential RNA expression in schizophrenia and bipolar disease
pp. 177-177(1)
Authors: Johnston N.; Torrey E.F.; Yolken R.H.

Viral transcription factor RNAs are differentially expressed in the brains of individuals with schizophrenia
pp. 177-177(1)
Authors: Yee F.; Torrey E.F.; Yolken R.H.

Molecular analyses of brains from individuals with schizophrenia--evidence of viral infections
pp. 177-178(2)
Authors: Yolken R.H.; Yee F.; Johnston N.; Leister F.; Bobo L.; Jafari N.; Ojeh C.; Torrey E.F.

Evidence of brain disgenesy in schizophrenia. A neuroanatomical controlled study from an asylum in Sao Paulo, Brazil
pp. 178-178(1)
Authors: Coura S.H.; Elkis H.

Development of neurons in the fetal cerebral cortex
pp. 178-178(1)
Authors: Garey L.J.; Yan X.X.

Neurogenesis in vitro of adult human olfactory epithelium
pp. 178-179(2)
Authors: Murrell W.; Bushell G.; Bates P.; Mackay-Sim A.; McGrath J.

Temporal lobe length reductions in schizophrenia--a post-mortem photographic study of unfixed brain from the runwell 3 series
pp. 179-179(1)
Authors: Crow T.J.; Crow L.R.

A study of sylvian fissure asymmetries in the runwell 3 series of psychotic brains
pp. 179-180(2)
Authors: Highley R.; Crow T.J.

Cytoarchitectural hippocampal asymmetries in schizophrenia
pp. 180-180(1)
Authors: Harrison P.J.; Eastwood S.L.; Esiri M.M.; Zaidel D.W.

The ultrastructure of the synapic contacts on the dopaminer-gic neurons in postmortem substantia nigra of schizophrenics
pp. 180-181(2)
Authors: Kolomeets N.S.; Uranova N.A.; Orlovskaya D.D.

Ultrastructural morphometric study of glio-synaptic relationships in post mortem caudate nucleus of schizophrenic patients
pp. 181-181(1)
Authors: Uranova N.A.; Orlovskaya D.D.; Denisov D.V.; Casanova M.F.; Devaughn N.

MRI of frozen brain tissue: a fresh look at morphometry in schizophrenia
pp. 181-181(1)
Authors: Doyle C.A.; Longson D.; Hutchinson C.; Simpson M.D.C.

Post mortem brain MRI; preliminary studies to optimise grey-white matter contrast, leading to assessment of structural and symmetry changes in schizophrenia
pp. 181-182(2)
Authors: Blamire A.; Rowe J.; Styles P.; McDonald B.

The postmortem diagnosis of schizophrenia--some psychosocial and clinical implications
pp. 182-182(1)
Authors: Roberts S.; Hill C.; Dean B.; Keks N.; Opeskin K.; Copolov D.

Selecting postmortem brain tissue for research: How important is the postmortem interval?
pp. 182-182(1)
Authors: Torrey E.F.; Johnston N.L.; Cervenak J.; Paltan J.D.; Yolken R.H.

Anomalous cerebral asymmetry in schizophrenia: a study of first episodes
pp. 183-183(1)
Authors: DeLisi L.E.; Sakuma M.; Xie S.-H.; Kushner M.; Finer D.L.; Hoff A.L.; Crow T.J.

Normal planum temporale asymmetry in familial schizophrenia: A volumetric MRI study
pp. 183-183(1)
Authors: Frangou S.; Sharma T.; Barta P.; Pearlson G.; Murray R.

A three dimensional mid sagittal plane for brain asymmetry measurement
pp. 183-184(2)
Authors: Guillemaud R.; Marais P.; Zisserman A.; McDonald B.; Crow T.J.; Brady M.

The temporal lobes, reversed asymmetry, and schizophrenia genetics
pp. 184-184(1)
Authors: Honer W.G.; Bassett A.S.; Squires-Wheeler E.; Falkai P.; Smith G.N.; Lapointe J.S.; Canero C.; Lang D.J.

Loss of cerebral asymmetry in familial schizophrenia--A volumetric MRI study using unbiased stereology
pp. 184-184(1)
Authors: Sharma T.; Lewis S.; Barta P.; Sigmundsson T.; Lancaster E.; Gurling H.; Pearlson G.; Murray R.M.

Mesiotemporal volumes and asymmetry in first episode schizophrenics: A baseline and follow-up study
pp. 184-184(1)
Authors: Strous R.D.; Ashtari M.; Bilder R.M.; Lieberman J.A.

Volumetric brain measurements in schizophrenia. First results of a multicentric MRI-study
pp. 185-185(1)
Authors: Falkai P.; Schneider T.; Pfeiffer U.; Schnabel J.; Bogerts B.

Hippocampal volume in adolescent schizophrenia
pp. 185-185(1)
Authors: Findling R.L.; Friedman L.; Buck J.; Cola D.; Kenny J.; Swales T.; Schulz S.C.

Temporal limbic and frontal changes in schizophrenia: a quantitative MRI study
pp. 185-185(1)
Authors: Schad L.R.; Essig M.; Knopp M.V.; Friedlinger M.; Frost S.; Schroder J.; Stockert A.; Gerdssen I.

Hypoplasia of the hippocampal formation and the entorhinal cortex detected in early-but not late-onset schizophrenia
pp. 186-186(1)
Authors: Nasrallah H.A.; Olson S.C.

Bilateral hippocampal volume reduction in chronic schizophrenia on MRI volumetric analysis
pp. 186-186(1)
Authors: Velakoulis D.; Pantelis C.; Cook M.J.; Murrie V.; Desmond P.M.; Tress B.M.; Brewer W.J.; Singh B.; Copolov D.

3-D surface analysis of the ventricular system in schizophrenia
pp. 186-186(1)
Authors: Buckley P.F.; Dean D.; Friedman L.; Kwon D.; Bookstein F.L.; Lewin J.S.; Kamath J.; Lys C.

Third ventricle enlargement in non-familial schizophrenia
pp. 186-187(2)
Authors: Burke J.G.; Reveley M.A.

An MRI volumetric study in schizophrenic patients
pp. 187-187(1)
Authors: Whitworth A.B.; Honeder M.; Kremser C.; Sperner B.; Felber S.; Stuppaeck C.H.; Fleischhacker W.W.

Distribution of ventricular brain ratio values in schizophrenic patients and normal subjects
pp. 187-187(1)
Authors: Vita A.; Dieci M.; Giobbio G.M.; Invernizzi G.; Braga M.

The maudsley family study of schizophrenia: a magnetic resonance imaging study of the corpus callosum in schizophrenic subjects, their relatives, and normal volunteers
pp. 187-188(2)
Authors: S. E.C.; Sharma T.; Woodruff P.; Murray R.M.

Quantitative neuroanatomic study of schizophrenia: landmark-based analysis
pp. 188-188(1)
Authors: DeQuardo J.R.; Bookstein F.L.; Brunberg J.A.; Tandon R.

Age at onset and sex differences in corpus callosum parameters in schizophrenia
pp. 188-188(1)
Authors: Scheller-Gilkey G.; Lewine R.J.

Volumes of frontal lobe subregions in schizophrenia: relation to cognitive function and clinical symptomatology
pp. 188-189(2)
Authors: Baare W.F.C.; Pol H.E.H.; Hijman R.; Kahn R.S.

Structure-function relations in first episode schizophrenia
pp. 189-189(1)
Authors: Bilder R.M.; Wu H.; Bogerts B.; Degreef G.; Chakos M.; Lieberman J.A.

Correlation between grey matter volume and syndrome scores in schizophrenia: a data-led approach
pp. 189-189(1)
Authors: Chua S.E.; McGuire P.K.; Wright I.C.; Poline J.-B.; Liddle P.F.; Murray R.M.; Frackowiak R.S.J.; Friston K.J.

Structural MRI and neuropsychological assessments in adolescent patients with either schizophrenia or affective disorders
pp. 189-190(2)
Authors: Friedman L.; Findling R.L.; Buck J.; Cola D.M.; Swales T.P.; Kenny J.T.; Schulz S.C.

Improvement of memory in patients following frontal lobe damage: a longitudinal follow-up study using 3D MR-imaging
pp. 190-190(1)
Authors: Pol H.E.H.; Hijman R.; Meyer P.; Tulleken C.A.F.; Ramos L.M.P.; Viergever M.A.; Kahn R.S.; van Ree J.M.

A comparison of the cognitive correlates of brain structure volumes in patients with schizophrenia and normal controls
pp. 190-190(1)
Authors: Rushe T.M.; Woodruff P.W.R.; Murray R.M.; Morris R.G.

Prefrontal cortical volumes and neuropsychological deficits in schizophrenia
pp. 190-191(2)
Authors: Ward P.B.; Loneragan C.; Ganser E.L.; Chaturverdi S.; Liebert B.; Redenbach J.; Langdon R.

A prospective follow-up study of brain morphology in 1st episode schizophrenia
pp. 191-191(1)
Authors: DeLisi L.E.; Sakuma M.; Polina D.; Grimson R.

Longitudinal course of brain morphology in first episode schizophrenia
pp. 191-191(1)
Authors: Lieberman J.; Koreen A.; Sheitman B.; Bilder R.; H. W.; Alvir J.

Qualitative brain assessment in schizophrenia, high risk subjects and normal controls on MRI
pp. 191-192(2)
Authors: Abukmeil S.S.; Lawrie S.M.; Hodges A.; Rimington E.; Grant E.M.; Byrne M.; Owens D.C.; Best J.J.; Johnstone E.C.

The computerised tomography rating scale for schizophrenia (CTRSS): validity and reliability
pp. 192-192(1)
Authors: Flynn S.W.; Falkai P.; Altman S.; MacEwan G.W.; Kopala L.; Smith G.N.; Ehmann T.S.; Honer W.G.

Gender differences in schizophrenia: brain morphology
pp. 192-192(1)
Authors: Nopoulos P.N.; Flaum M.A.; Andreasen N.C.

Dopaminergic modulation of abnormal brain activations in untreated schizophrenia
pp. 193-193(1)
Authors: Fletcher P.C.; Grasby P.M.; Frith C.D.; Friston K.J.; Frackowiak R.S.J.; Dolan R.J.

Functional MRI of covert verbal fluency
pp. 193-193(1)
Authors: Grasby P.; Webster P.; Williams S.; Bullmore E.; Brammer M.; Checkley S.

Functional neuroanatomy of verbal self-monitoring
pp. 193-193(1)
Authors: McGuire P.K.; Silbersweig D.A.; Frith C.D.

A spet study of word generation in schizophrenia and epilepsy
pp. 193-194(2)
Authors: Mellers J.D.C.; Adachi N.; Takei N.; Cluckie A.; Toone B.K.; Lishman W.A.

Symptom dimensions in psychotic disorder and regional cerebral glucose metabolism using ¹⁸F-fluorodeoxyglucose and positron emission tomography
pp. 194-194(1)
Authors: Al-Mousawi A.H.; Evans N.; Roeda D.; Chaloner F.; Ashcroft G.W.

rCBF pattern contrasts between normal volunteers and medication-free schizophrenics derived from a difficult tone recognition task
pp. 194-194(1)
Authors: Holcomb H.H.; Lahti A.C.; Caudill P.J.; Zhao Z.; Medoff D.R.; Carpenter W.T.; Albert P.K.; Tamminga C.A.

Regional cerebral blood flow in patients with schizophrenia: relevance to symptom structures
pp. 195-195(1)
Authors: Kawasaki Y.; Maeda Y.; Sakai N.; Higashima M.; Yamaguchi N.; Koshino Y.

rCBF pattern differences between medication-free schizophrenic patients with and without deficit symptoms
pp. 195-195(1)
Authors: Lahti A.C.; Holcomb H.H.; Carpenter W.T.; Caudill P.J.; Zhao M.; Albert P.K.; Medoff D.R.; Tamminga C.A.

The use of functional MRI to study hallucinations
pp. 195-195(1)
Authors: David A.; Howard R.; Woodruff P.; Bullmore E.; Brammer M.; Mellers J.; Williams S.

Task performance and cerebral activation during a simple motor task: a study with functional magnetic resonance imaging
pp. 196-196(1)
Authors: Schroder J.; Baudendistel K.; Essig M.; Schad L.R.; Wenz F.; Knopp M.V.; Jahn T.

Cortical glucose metabolism in male schizophrenic patients and controls matched for CPT performance
pp. 196-196(1)
Authors: Siegel B.V.; Fleming K.; Nuechterlein K.H.; Buchsbaum M.S.

Neural correlates of the experience of auditory hallucinations in schizophrenia
pp. 196-196(1)
Authors: Woodruff P.; David A.; Howard R.; Mellers J.; Brammer M.; Bullmore E.; Wright I.; Barker G.; Williams S.

Limbic system dysfunctions in schizophrenia and mania using ¹⁸F-fluorodeoxyglucose and positron emission tomography
pp. 197-197(1)
Authors: Al-Mousawi A.H.; Evans N.; Roeda D.; Chaloner F.; Ashcroft G.W.

Hippocampal NAA depletion in psychosis: 1H MRS in schizophrenia and temporal lobe epilepsy
pp. 197-197(1)
Authors: Maier M.; Ron M.A.; Trimble M.; Mellers J.; Toone B.

¹¹C-way 100635: a pet tracer for the 5HT_1A receptor
pp. 197-198(2)
Authors: Bench C.J.; Lammertsma A.A.; Pike V.W.; Hume S.P.; Cliffe I.A.; Fletcher A.; Grasby P.M.

Decrease of D1-dopamine receptor binding in the frontal cortex of neuroleptic naive schizophrenic patients measured by pet
pp. 198-198(1)
Authors: Karlsson P.; Farde L.; Halldin C.; Sedvall G.

Spect imaging of synaptic dopamine release in drug free schizophrenic patients: an experimental validation of the dopamine hypothesis of schizophrenia
pp. 198-199(2)
Authors: Laruelle M.; Abi-Dargham A.; Gil R.; van Dyck C.H.; Erdos J.; D'Souza D.; Rosenblatt W.; McCance-Katz E.; Zea-Ponce Y.; Zoghbi S.S.; Baldwin R.M.; Hoffer P.B.; Krystal J.; Charney D.S.; Innis R.B.

Benzodiazepine GABA-A receptor binding in schizophrenia--a study with single photon emission tomography and ¹²³I-iomazenii
pp. 199-199(1)
Authors: Lawrie S.M.; Ebmeier K.P.; Verhoeff N.P.L.G.; Van Royen E.A.; Johnstone E.C.; Goodwin G.M.

D2- and 5-HT2 receptor occupancy in ''mega-dose'' treated schizophrenic patients
pp. 199-199(1)
Authors: Nyberg S.; Farde L.; Dencker S.-J.; Malm U.; Dahl M.-L.; Halldin C.

Long-time persistence of D₂ dopamine receptor occupancy after discontinuation of haloperidol decanoate
pp. 199-200(2)
Authors: Nyberg S.; Farde L.; Halldin C.

Dopamine D2 receptor binding in drug naive, first break schizophrenics: a ¹²³I-IBZM single photon emission computerised tomography study
pp. 200-200(1)
Authors: Schroder J.; Bubeck B.; Silvestri S.; Demisch S.; Sauer H.

Dopamine D2-receptor occupancy under NL treatment in schizophrenic and depressed patients
pp. 200-200(1)
Authors: Scherer J.; Tatsch K.; Schwarz J.; Albus M.

Laterality and psychosis: a study using ¹⁸F-fluorodeoxyglucose and positron emission tomography
pp. 200-201(2)
Authors: Al-Mousawi A.H.; Evans N.; Roeda D.; Chaloner F.; Ashcroft G.W.

Ocular motor stimulation in schizophrenics with smooth pursuit eye movement disorders a ^99mTc-ECD spect study
pp. 201-201(1)
Authors: Gerdsen I.; Pinkert J.; Fotzsch R.; Oehme L.; Bach O.; Franke W.-G.

Effects of antipsychotic medications on cognition and cerebral blood flow
pp. 201-201(1)
Authors: Miller D.D.; Cizadlo T.; Hichwa R.D.; Andreasen N.C.

Brain imaging to determine the effects of sertindole in a double-blind, placebo-controlled trial in schizophrenic patients
pp. 201-202(2)
Authors: Potkin S.; Zborowski J.; Wu J.; Giles K.; Bera R.; Henry M.; Sebree T.; Aurang C.; Wallin B.; Bunney W.

Functional neuroimaging in schizophrenia with religious delusions
pp. 202-202(1)
Authors: Puri B.K.; Bagary M.; Nijran K.S.; Ahmed F.; Lekh S.K.; Richardson A.J.

Diazepam and lorazepam binding in schizophrenia: a study with iomazenil-spect
pp. 202-203(2)
Authors: Schroder J.; Demisch S.; Bubeck B.; Sauer H.

Willed movement in schizophrenia: a pet study
pp. 203-203(1)
Authors: Spence S.A.; Hirsch S.R.; Liddle P.F.; Meehan J.; Brooks D.J.; Grasby P.M.

³¹P-magnetic resonance spectroscopy in the dorsolateral prefrontal cortex of schizophrenics and depressed patiens
pp. 203-203(1)
Authors: Volz H.P.; Sauer H.; Rzanny R.; Kaiser W.A.

Thought disorder in schizophrenia reflects general cognitive impairment and not focal linguistic dysfunction
pp. 205-205(1)
Authors: Blakey A.F.; Hellewell J.S.E.; Deakin J.F.W.

Latent inhibition is not reduced in drug-free patients with schizophrenia
pp. 205-205(1)
Authors: Williams J.H.; Wellman N.A.; Geaney D.P.; Cowen P.J.; Feldon J.; Rawlins J.N.P.

Syntactic functioning of preschizophrenic children
pp. 205-206(2)
Authors: Done J.; Crow T.J.; Sacker A.; Leinonen E.; Bevis K.

'Theory of mind' and executive function in schizophrenia
pp. 206-206(1)
Authors: Pickup G.J.; Frith C.D.

Theory of mind and other cognitive deficits in schizophrenia
pp. 206-206(1)
Authors: Stephenson D.; Hellewell J.S.E.; Deakin J.F.W.; Corcoran R.; Frith C.D.

Relatives of schizophrenic patients show impaired design fluency and working memory
pp. 206-207(2)
Authors: Blakey A.F.; Hellewell J.S.E.; Deakin J.F.W.

Biological relatives of schizophrenic patients show impairments in semantic memory
pp. 207-207(1)
Authors: Bonser K.M.; Roxborough H.M.; Hellewell J.

Syndrome specificity of reversible recognition memory impairments in schizophrenia
pp. 207-207(1)
Authors: Gruzelier J.H.; Richardson A.J.; Wilson L.

Memory impairment in schizophrenia--evidence for impaired access rather than a defect in encoding
pp. 207-208(2)
Authors: Hellewell J.E.; Hewitt J.; Stirling J.

Retention in schizophrenia patients on two working memory tasks
pp. 208-208(1)
Authors: Hijman R.; Pol H.E.H.; Baare W.F.C.; Talma H.; van der Linden J.; Kahn R.S.

Visuospatial memory in first episode schizophrenia
pp. 208-208(1)
Authors: Hutton S.B.; Puri B.K.; Barnes T.R.E.; Joyce E.M.; Robbins T.W.

Laboratory and clinical tests of spatial working memory
pp. 208-209(2)
Authors: Keefe R.S.E.; Roitman S.E.L.; Dupre R.L.; Harvey P.D.

Relationship of attentional and organizational capacity to recent memory performance in schizophrenia and other psychotic disorders
pp. 209-209(1)
Authors: G. P.L.; Haverstock S.L.; Kitchens A.S.

Memory and intellectual functioning in familial and non familial schizophrenic subjects
pp. 209-209(1)
Authors: Mockler D.M.; Murray R.M.; Frangou S.; Sigmunsson T.; Sharma T.

Memory and intellectual impairment in familial schizophrenia
pp. 209-210(2)
Authors: Mockler D.M.; Murray R.M.; Sigmunsson T.; Sharma T.

Neuropsychological differences in non familial schizophrenic subjects and their first degree relatives
pp. 210-210(1)
Authors: Mockler D.M.; Murray R.M.; Frangou S.; Sigmunsson T.; Sharma T.

A comparison of memory and intellectual decline in schizophrenia and healthy controls
pp. 210-210(1)
Authors: Mockler D.M.; Riordan J.M.; Sharma T.

Planning and visuospatial working memory in schizophrenia
pp. 210-211(2)
Authors: Morris R.G.; Rushe T.; Woodruff P.W.R.; Murray R.M.

Memory impairment in schizophrenia: its relationship to executive function
pp. 211-211(1)
Authors: Nathaniel-James D.A.; Brown R.; Ron M.A.

Working memory and remediation of Wisconsin card sorting test performance in schizophrenia
pp. 211-211(1)
Authors: Mancini F.; Mattei P.; Daneluzzo E.; Nardone A.; Prosperini P.; Casacchia M.; Rossi A.; Stratta P.

Evidence that manual dominance and lateralisation of a letter-matching task are decoupled in schizophrenia
pp. 212-212(1)
Authors: Calvert G.A.; Geddes J.; Crow T.J.; Norman W.D.; Iversen S.D.

A test of bimanual coordination: evidence for intact kinesthetic self-monitoring in schizophrenia?
pp. 212-212(1)
Authors: Calvert G.; Geddes J.; Crow T.J.; Iversen S.D.

Hand preference and hand skill in schizophrenic patients: findings from the 1946 birth cohort
pp. 212-213(2)
Authors: Cannon M.; Jones P.B.; Murray R.M.; Wadsworth M.E.J.

The maudsley family study: dichotic listening in schizophrenics, their relatives, and normal volunteers
pp. 213-213(1)
Authors: S. E.C.; David A.S.; King H.; Sharma T.; Murray R.M.

Low cardiovagal tone in schizophrenia: brain laterality & clinical features
pp. 213-213(1)
Authors: Malaspina D.; Bruder G.; Dalack; Storer S.; Glassman A.; Gorman J.; Kaufmann C.

Functional laterality and cognitive ability
pp. 213-214(2)
Authors: Sakuma M.; DeLisi L.E.; Hoff A.L.

Is the physiological hemispheric asymmetry reversed in schizophrenia?
pp. 214-214(1)
Authors: Sauer H.; Huonker R.; Volz H.P.; Nowak H.; Rieke K.; Hajek M.

Mixed handedness in familial and sporadic schizophrenia
pp. 214-214(1)
Authors: Taylor M.; Sharma T.; Takei N.; Murray R.M.

Motor speed, laterality and bimanual coordination in schizophrenia
pp. 214-214(1)
Author: Weller M.P.I.

Lateralised differences in tapping speed in schizophrenia
pp. 215-215(1)
Authors: Weller M.P.I.; Calev A.; Chazen S.; Nigal D.; Tubi N.; Kidd J.; Lerer B.

Handedness responses in schizophrenia
pp. 215-215(1)
Authors: Weller M.P.I.; Hall J.; Latimer-Sayer T.

Anti-saccade abnormality in familial schizophrenic patients and first-degree relatives: the Maudsley family study
pp. 215-215(1)
Authors: Crawford T.J.; Sharma T.; Lech S.; Puri B.K.; Kennard C.; Murray R.M.; Lewis S.W.L.

Smooth pursuit eye movements in schizophrenia and major depression
pp. 215-216(2)
Authors: Flechtner K.-M.; Steinacher B.; Sauer R.; Mackert A.

Dissociation between vulnerability and illness markers of eye movement control in schizophrenia
pp. 216-216(1)
Authors: Hellewell J.S.E.; Deakin J.F.W.

Saccadic and smooth pursuit eye movement abnormalities in first episode schizophrenia
pp. 216-216(1)
Authors: Hutton S.B.; Crawford T.J.; Puri B.K.; Kennard C.; Joyce E.M.; Barnes T.R.E.

A cognitive neuropsychiatric approach to the study of delusions in schizophrenia using visual scan paths
pp. 216-217(2)
Authors: Phillips M.L.; David A.S.

Saccadic error rates predict the psychomotor poverty syndrome in schizophrenia
pp. 217-217(1)
Authors: Reveley M.A.; Crawford T.; Haegar B.; Kennard C.; Henderson L.

An investigation of the validity of neuropsychological deficits and eye movement dysfunctions as genetic vulnerability markers for schizophrenia in av twin sample
pp. 217-217(1)
Authors: Ribchester T.; Marshall J.E.; Murray R.; Hemsley D.; Reveley A.M.

Reduced visual motion sensitivity in unmedicated schizophrenic patients
pp. 217-218(2)
Authors: Richardson A.J.; Gruzelier J.H.; Puri B.K.

Eye movements, spatial short-term memory, and functional visual field in schizophrenia
pp. 218-218(1)
Authors: Streit M.; Wolwer W.; Kiesow S.; Gaebel W.

Visuomotor integration and cognitive flexibility in schizophrenia
pp. 218-218(1)
Authors: Wolwer W.; Kiesow S.; Streit M.; Gaebel W.

The perception of gaze and attention in schizophrenia
pp. 218-219(2)
Authors: Jayasekera A.I.; Hellewell J.S.E.; Deakin J.F.W.; Perrett D.I.

Dissociation of face affect identification and unfamiliar face recognition in schizophrenia
pp. 219-219(1)
Authors: Whittaker J.F.; Deakin J.F.W.

Visualising what patients see as emotions in faces
pp. 219-220(2)
Authors: Whittaker J.F.; Lanitis A.; Deakin J.F.W.; Cootes T.F.; Taylor C.J.

Antisaccade, executive and clinical measures in schizophrenia are unaffected by acute 5HT2A/2C antagonism using cyproheptadine
pp. 220-220(1)
Authors: Chaudhry I.B.; Soni S.D.; Hellewell J.S.E.; Deakin J.F.W.

Cognitive dysfunction in schizophrenia: a comparison of the impact of zotepine versus clozapine on the syndrom (a double blind trial)
pp. 220-220(1)
Authors: Gallhofer B.; Ulferts J.; Bauer U.; Gruppe H.

The effects of clozapine and haldol on memory functioning in treatment refractory schizophrenics
pp. 221-221(1)
Authors: Goldman R.S.; Bates J.A.; Bilder R.M.; Kane J.; Schooler N.; Marder S.

Nicotine-haloperidol interactions and cognitive performance in schizophrenia
pp. 221-221(1)
Authors: Levin E.D.; McEvoy J.P.; Wilson W.H.; Rose J.E.

Neuropsychological change to clozapine
pp. 221-221(1)
Authors: Purdon S.E.; Jones B.; Labelle A.; Boulay L.

Saccadic eye movement (SEM) abnormalities in schizophrenic patients treated with clozapine, risperidone or sulpiride
pp. 222-222(1)
Authors: Reveley M.A.; Burke J.G.; Dursun S.M.; Andrews H.; Patel J.K.M.; Simms M.

The effect of clozapine treatment on mismatch negativity
pp. 222-222(1)
Authors: Umbricht D.; Novak G.; Javitt D.; Pollack S.; Lieberman J.; Kane J.

Opposite treatment effects on negative priming in patients with affective psychoses or schizophrenia
pp. 222-223(2)
Authors: Williams J.H.; Wellman N.A.; Geaney D.P.; Cowen P.J.; Feldon J.; Rawlins J.N.P.

Haloperidol reduces stroop interference and increases negative priming in healthy people
pp. 223-223(1)
Authors: Williams J.H.; Wellman N.A.; Geaney D.P.; Cowen P.J.; Feldon J.; Rawlins J.N.P.

Contrasts in neuropsychological test profile between first episode patients with schizophrenia or affective disorders
pp. 223-223(1)
Authors: Albus M.; Hubmann W.; Sobizack N.; Wahlheim C.; Mohr F.

Neuropsychological impairment in first episode and chronic schizophrenic patients
pp. 223-224(2)
Authors: Albus M.; Hubmann W.; Ehrenberg C.; Forcht U.; Mohr F.; Sobizack N.; Wahlheim C.

Cognitive and social functioning in schizophrenia outpatients who abuse substances
pp. 224-224(1)
Authors: Addington J.; Addington D.

Therapy monitoring with prepulse inhibition in an active auditory discrimination in patients with schizophrenia
pp. 224-224(1)
Authors: Bender S.; Wolstein J.; Butorac M.; Grzella I.; Ortmann K.; Zerbin D.; Schall U.; Oades R.D.

Olfactory and neuropsychological deficits in first episode psychosis
pp. 224-225(2)
Authors: Brewer W.J.; Smith D.J.; Velakoulis D.; Anderson V.; McGorry P.; Copolov D.; Singh B.; Pantelis C.

Neuropsychological and neurological change in Schizophrenia: a four-year longitudinal study
pp. 225-225(1)
Authors: Clair A.L.; Boschen M.

Disorder of automatic attention in schizophrenic patients
pp. 225-225(1)
Authors: Di Michele V.; Ladavas E.

Cognitive functions and psychopathological dimensions in schizophrenia
pp. 225-226(2)
Authors: Galderisi S.; Mucci A.; Argenziano G.; Maj M.

Cognitive dysfunction in schizophrenia: functional disconnection of dorso-lateral prefrontal cortex and basal ganglia
pp. 226-226(1)
Author: Gallhofer B.

Global/local task indices of hemispheric and attentional functions in schizophrenia
pp. 226-227(2)
Authors: Granholm E.; Perry W.; Nelson P.; Braff D.

Cognitive decline in geriatric chronic schizophrenic patients: evidence for a neurodegenerative process?
pp. 227-227(1)
Authors: Harvey P.D.; Silverman J.; Powchik P.; Mohs R.C.; Davidson M.

Are deluded people logical in their reasoning?
pp. 227-227(1)
Authors: Kemp R.; S. C.; McKenna P.; David A.

Pharmacology of sensory gating in the ascending auditory system of the pigeon (Columba livia)
pp. 227-228(2)
Authors: Keysers C.; Kast B.; Schall U.

Developmental pathways in epilepsy and schizophrenia compared
pp. 228-228(1)
Authors: Leask S.J.; Done D.J.; Crow T.J.

Common sense, insight, and neuropsychological test performance in patients with schizophrenia
pp. 228-228(1)
Authors: McEvoy J.P.; Hartman M.; Gottlieb D.; Godwin S.; Apperson L.J.; Wilson W.H.

Is there a link between neuropsychological dysfunction and soft neurological signs in schizophrenia?
pp. 228-228(1)
Authors: Morris M.; Lane A.; Burke T.; Larkin C.; O'Callaghan E.

Relationships between schizotypy, within-subject latent inhibition and prepulse inhibition
pp. 229-229(1)
Authors: Morton N.; Gray N.S.; Mellers J.D.C.; Toone B.K.; Gray J.A.

Cognitive performance during recovery from schizophrenia
pp. 229-229(1)
Authors: Puschel J.; Rentsch M.; Stassen H.H.; Regard M.

Estimating premorbid IQ in schizophrenia
pp. 229-229(1)
Authors: Russell A.J.; Munro J.; Jones P.B.; Hemsley D.; Murray R.M.

Executive dysfunction in schizophrenia intimately related to negative symptoms
pp. 229-230(2)
Authors: Coakley G.; Youssef H.A.; Waddington J.L.; Scully P.

Schizophrenics show reduced stroop interference if long-latency responses are excluded
pp. 230-230(1)
Authors: Williams J.H.; Wellman N.A.; Geaney D.P.; Cowen P.J.; Feldon J.; Rawlins J.N.P.

Response inhibition: a stable vulnerability factor in chronic schizophrenia
pp. 230-230(1)
Author: Wykes T.

Event-related potentials and selective attention in healthy volunteers and schizophrenic patients with negative syndrome
pp. 231-231(1)
Author: Eichert V.

Structural correlates of event-related abnormalities in familial schizophrenia
pp. 231-231(1)
Authors: Frangou S.; Sharma T.; Lancaster E.; Honeycut N.; Barta P.; Pearlson G.; Murray R.

Auditory hallucinations in schizophrenia: a combined ERP and MRI investigation
pp. 231-232(2)
Authors: Levitan C.; Ward P.B.; Catts S.V.; Hemsley D.R.

P300 Lateral asymmetries in schizophrenic syndromes
pp. 232-232(1)
Authors: Richardson A.J.; Gruzelier J.H.; Liddiard D.M.; Cheema S.; Puri B.K.

Correlations between P300 abnormalities and verbal memory deficits in schizophrenia
pp. 232-232(1)
Authors: Shajahan P.M.; O'Carroll R.E.; Blackwood D.H.R.

Deficits in generation of auditory event-related potentials, neuropsychological performance and psychopathology in chronic schizophrenia
pp. 232-232(1)
Authors: Umbricht D.; Novak G.; Bilder R.; Javitt D.; Bates J.; Pollack S.; Lieberman J.; Kane J.

Relationships between psychopathology and EEG-variables in schizophrenic patients with negative syndrome
pp. 233-233(1)
Authors: Eichert V.; Klosterkotter J.

Cortico-cortical connectivity measured with EEG coherence in early versus late maturers: developmental implications for schizophrenia
pp. 233-233(1)
Authors: Kaiser J.; Gruzelier J.H.

Spectral analysis of the EEG in schizophrenia
pp. 233-233(1)
Authors: McEvedy C.J.B.; Basquille J.

Clozapine-induced EEG changes as a function of clozapine serum levels
pp. 233-234(2)
Authors: McEvoy J.P.; Freudenreich O.; Weiner R.D.

Changes of MMN amplitude and topography in patients with paranoid and nonparanoid schizophrenia or obsessive compulsive disorder
pp. 234-234(1)
Authors: Oades R.D.; Grzella I.; Dittmann-Balcar A.; Zerbin D.

The effects of antipsychotic medication on electromyographic responses to transcranial magnetic stimulation of the motor cortex in schizophrenic patients
pp. 234-234(1)
Authors: Puri B.K.; Davey N.J.; Lewis S.W.

Electromyographic responses of thenar muscles to transcranial magnetic stimulation of the motor cortex in schizophrenia
pp. 234-235(2)
Authors: Puri B.K.; Davey N.J.; Lewis H.S.; Ellaway P.H.; Lewis S.W.

Abnormalities of brainstem evoked potentials and CT-scan as early predictors for 5-year outcome in schizophrenic patients
pp. 235-235(1)
Authors: Wieselgren I.-M.; Lindstrom L.H.; Lindstrom E.; Svedberg A.

Plasma interleukin-1 and sleep architecture in schizophrenia and other non affective psychoses
pp. 235-235(1)
Authors: Appelberg B.; Katila H.; Rimon R.

State-trait aspects of polysomnographic abnormalities in schizophrenia
pp. 235-236(2)
Authors: Tandon R.; Shipley J.; Taylor S.; Goldman M.; Maixner S.; Goodson J.

The effects of EE on the long term course of schizophrenic illness-results of an 8 years follow-up
pp. 237-237(1)
Authors: Monking H.S.; Stricker K.

The munsteraner familienbogen (MFB)--an instrument to examine expressed emotion (EE)
pp. 237-237(1)
Authors: Stricker K.; Monking H.S.

Links between expressed emotion (EE) and burden of care in relatives of those suffering from schizophrenia: a follow-up study
pp. 237-237(1)
Authors: Scazufca M.; Kuipers E.

Demographic and clinical predictors of criticism and hostility in relatives of patients with schizophrenia or related psychosis
pp. 238-238(1)
Authors: Bentsen H.; Notland T.H.; Boye B.; Munkvold O.-G.; Bjorge H.; Lersbryggen A.B.; Uren G.; Oskarsson K.H.; Berg-Larsen R.; Lingjaerde O.; Malt U.F.

Quality of life in schizophrenia: its relationship to sociodemographic factors, symptomatology and tardive dyskinesia
pp. 238-238(1)
Authors: Browne S.; Roe M.; Lane A.; Gervin M.; Morris M.; Kinsella A.; Larkin C.; O'Callaghan E.

Factors associated with multiple admissions to a public psychiatric hospital
pp. 238-238(1)
Authors: Vogel-Binyet S.; Huguelet P.

An inventory of chronic, mentally disabled schizophrenic outpatients
pp. 239-239(1)
Authors: Flyckt L.K.; Taube A.; Edman G.V.; Jedenius E.

Use of psychiatric services by patients with schizophrenia and related psychoses
pp. 239-239(1)
Authors: Menezes P.R.; Mann A.H.

Follow-up study of a group of schizophrenic patients and their involvement in religious activities
pp. 239-240(2)
Authors: Huguelet P.; Vogel-Binyet S.; Gonzalvez C.; McQuillan A.

National needs assessment of long-stay hospitalized schizophrenic patients in Israel
pp. 240-240(1)
Authors: Rabinowitz J.; Mark M.

The needs of parents with serious mental illness
pp. 240-240(1)
Authors: Hearle J.; McMullen S.; McGrath J.; Dark F.

The effect of psychosocial rehabilitation on quality of life and symptomatology in schizophrenia
pp. 240-240(1)
Authors: Browne S.; Roe M.; Lane A.; Gervin M.; Morris M.; Kinsella A.; Larkin C.; O'Callaghan E.

Treatment costs of schizophrenic patients
pp. 241-241(1)
Authors: De Hert M.; Thys E.; Boydens J.; Gilis P.; Kesteloot K.; Verhaegen L.; Peuskens J.

The description of characteristics of HIV seroconversion in schizophrenic patients and of a prevention program
pp. 241-241(1)
Authors: Fuciec M.; Huguelet P.; Vogel-Binyet S.; Favrod J.

Neurological signs in schizophrenia
pp. 243-243(1)
Authors: Clair A.; Mann P.

Pfropf-schizophrenie revisited
pp. 243-243(1)
Authors: Doody G.A.; Owens D.G.C.; Johnstone E.C.

Awareness of psychopathology, extrapyramidal symptoms and subjective depression in outpatients attending for antipsychotic depot injection
pp. 243-243(1)
Authors: Godfrey J.M.; Al-Mousawi A.H.; Hughes A.; Jeffries C.

Photophobia and photophilia in psychotic patients
pp. 244-244(1)
Authors: Gerbaldo H.; Maurer K.

Physical exercise and pituitary-adrenal function in children with autistic-like disorder: relevance to schizophrenia
pp. 244-244(1)
Authors: Wied C.C.G.-d.; Jansen L.M.C.; van der Gaag R.J.; van Engeland H.

Olfactory deficits in familial schizophrenia
pp. 244-244(1)
Authors: Kopala L.C.; Bassett A.S.; Morrison K.; Good K.; Honer W.G.

Schizophrenia research activities in non-English speaking countries (13 EEC and 4 Asian countries): A MEDLINE survey
pp. 245-245(1)
Authors: Takei N.; Verdoux H.; Nanko S.

Comparison of research versus nonresearch schizophrenic patients
pp. 245-245(1)
Authors: Tandon R.; Patel B.; Reddig S.; Taylor S.F.; DeQuardo J.R.

Attitudes of mental health nurses towards patient involvement in research
pp. 245-245(1)
Authors: Vacca J.; Marsden W.; Meehan T.